Preferred Label : NKp46/CD16/CD20/IL-2-variant-specific NK Cell Engager IPH6501;
NCIt synonyms : ANKET IPH6501; Tetraspecific ANKET IPH6501; Antibody-based NK Cell Engager Therapeutic Agent IPH6501;
NCIt definition : A tetra-specific natural killer (NK) cell engager composed of antibody fragments directed
against the two NK cell activating receptors NKp46 and CD16a (FcgammaRIIIa), an antibody
fragment against the tumor-associated antigen (TAA) CD20 and a non-alpha interleukin-2
variant (IL-2v), composed of the beta chain (CD122) of the interleukin-2 receptor
(IL-2R), with potential immunomodulating and antineoplastic activities. Upon administration,
the NKp46/CD16/CD20/IL-2-variant-specific NK cell engager IPH6501 targets and binds
with the anti-NKp46 moiety to the activating receptor NKp46 expressed on tumor-infiltrating
NK cells, and with Fc gamma to the activating receptor CD16, also expressed on NK
cells. In addition, IPH6501 targets and binds, with its IL-2v moiety, to IL-2Rbeta
on NK cells, and with its anti-CD20 antibody moiety to CD20 that is expressed on tumor
cells. This bridges cancer cells and NK cells, stimulates NK cell proliferation and
activation, and allows for NK cell-mediated cytokine secretion and cytotoxicity against
CD20-expressing cancer cells. This depletes CD20-expressing tumor cells. CD20 is overexpressed
on a variety of tumor cell types. IL-2R enhances NK cell proliferation. NKp46 enhances
NK cytokine production. IL-2v does not bind to the IL-2R-alpha chain (CD25) and does
not interact with regulatory T-cells (Tregs). Co-engagement of NKp46 and CD16 triggers
strong NK cell activation.;
Molecule name : IPH 6501; IPH-6501;
NCI Metathesaurus CUI : CL1922112;
Origin ID : C202938;
UMLS CUI : C5854566;
Semantic type(s)
- concept_is_in_subset
- has_target
